Table 3. CD33 expression and MDR... | American Society of Hematology

Table 3.

CD33 expression and MDR function in leukemic samples

		DiOC₂ efflux*			CD33†
Patient	Leukemia type (FAB)	D efflux	D ± CsA	% positive cells	MFI‡
1	AML (M1)	0.57	0.17	94	312
4	AML (M1)	0.58	0.29	93	437
8	AML (M1)	0.48	0.22	94	63
2	AML (M2)	0.58	0.13	94	41
5	AML (M2)	0.63	0.64	80	103
6	AML (M2)	ND	ND	85	80
7	AML (M2)	0.56	0.31	99	434
10	AML (M2)	0.16	0.12	89	43
3	AML (M4)	ND	ND	71	100
9	AML (M5)	0.84	0.71	73	185

		DiOC₂ efflux*			CD33†
Patient	Leukemia type (FAB)	D efflux	D ± CsA	% positive cells	MFI‡
1	AML (M1)	0.57	0.17	94	312
4	AML (M1)	0.58	0.29	93	437
8	AML (M1)	0.48	0.22	94	63
2	AML (M2)	0.58	0.13	94	41
5	AML (M2)	0.63	0.64	80	103
6	AML (M2)	ND	ND	85	80
7	AML (M2)	0.56	0.31	99	434
10	AML (M2)	0.16	0.12	89	43
3	AML (M4)	ND	ND	71	100
9	AML (M5)	0.84	0.71	73	185

ND indicates not done.

DiOC₂ efflux activity and the effect of CsA on efflux are expressed as D values as described in Table 1.

Percentage of CD33 was measured by direct immunofluorescence.

MFI indicates mean fluorescence intensity.